Can Wearables Become Clinical Tools? | Longevity News Roundup — Week 24, 2026

Why It Matters

Wearable sensors and AI‑driven platforms are transitioning from consumer curiosities to actionable clinical tools, accelerating personalized longevity care and creating new regulatory and market dynamics.

Key Takeaways

• Longevitics launches AI platform integrating labs, wearables, notes for clinicians.
• Platform faces validation challenges and potential gender bias in recommendations.
• Rejuvenate Bio secures $6M partnership with Merck Health for animal longevity therapies.
• Continuous cortisol wearable captures awakening response, promising early metabolic disorder detection.
• Wearable cortisol data could transform women’s health monitoring and stress management.

Summary

The episode explores how emerging AI platforms and wearables are moving into clinical longevity practice, covering Longevitics’ new intelligence system, a continuous cortisol sensor, and a landmark animal‑health partnership.

Longevitics aggregates labs, wearable streams, notes and intake forms, then runs them through fifteen organ‑specific AI models to generate physician‑ready summaries. The hosts stress the need for independent validation, noting risks of bias—especially for female patients—and the current lack of standardized protocols.

Rejuvenate Bio’s $6 million deal with Merck Health brings a major animal‑health player into age‑targeted gene‑therapy research, positioning pets and livestock as a proving ground for human longevity therapeutics. Meanwhile, Adaptics Biosciences demonstrated a wearable that continuously tracks free cortisol, capturing the awakening response and overnight lows—patterns missed by single blood or saliva tests.

If validated, these tools could reshape preventive care: AI‑driven data synthesis may relieve clinicians’ overload, continuous hormone monitoring could flag metabolic risk early, and animal‑health pipelines may accelerate human drug development. Regulatory frameworks and data‑ownership models will be critical as the industry shifts from novelty gadgets to trusted clinical diagnostics.

Original Description

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine clinical AI, cortisol wearables, blood pressure monitoring, animal longevity biotech, stem cell therapies and next-generation obesity treatments.

- Longevitix launched a clinical intelligence platform designed for longevity, preventive and functional medicine clinics. The system combines laboratory results, wearable data, clinical notes and patient histories into physician-ready summaries, prioritized insights and personalized intervention plans.

- Rejuvenate Bio secured $6 million in new financing alongside a strategic collaboration with Merck Animal Health. The partnership aims to advance gene therapies for chronic and age-related conditions in pets, highlighting growing interest in animal longevity as a pathway for translational research.

- Adaptyx Biosciences presented data on a wearable cortisol sensor capable of continuously tracking free cortisol over multiple days. The device successfully captured daily cortisol rhythms and showed strong agreement with paired blood measurements.

- Celularity partnered with Fountain Life to offer placental-derived cell therapies at Fountain Life’s Florida facility. The collaboration leverages Florida’s evolving framework for early-stage stem cell treatments and could provide valuable real-world clinical data.

- South Korea became the first country to include Skylabs’ Cart BP Pro in its national hypertension treatment guidelines. The ring-shaped device continuously monitors blood pressure without the need for a traditional arm cuff, helping detect risks that often go unnoticed during routine clinic visits.

- MitoRx presented preclinical data for MTRX31, a mitochondrial-targeted obesity therapy designed to improve metabolic health through a mechanism distinct from GLP-1 drugs. The approach could serve as either a standalone treatment or a complementary therapy, making it a potentially attractive target for future pharmaceutical partnerships.

----------

News & References:

- Longevitix launches AI platform to tackle longevity data overload → https://longevity.technology/news/longevitix-launches-ai-platform-to-tackle-longevity-data-overload/

- Rejuvenate Bio secures funding and Merck partnership → https://longevity.technology/news/rejuvenate-bio-secures-funding-and-merck-partnership/

- Adaptyx debuts first continuous cortisol tracking wearable → https://longevity.technology/news/adaptyx-debuts-first-continuous-cortisol-tracking-wearable/

- Celularity, Fountain Life to offer experimental cell therapy in Florida → https://longevity.technology/news/celularity-fountain-life-to-offer-experimental-cell-therapy-in-florida/

- Goodbye, arm cuffs? South Korea bets on ring-type BP monitor → https://longevity.technology/news/goodbye-arm-cuffs-south-korea-bets-on-ring-type-bp-monitor/

- MitoRX’s new obesity drug targets metabolism, not appetite → https://longevity.technology/news/mitorxs-new-obesity-drug-targets-metabolism-not-appetite/